Etuvetidigene autotemcel

FDA Drug Profile — WASKYRA

Etuvetidigene autotemcel is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including WASKYRA. Available dosage form: injection.

Drug details

Generic Name
Etuvetidigene autotemcel
Brand Names
WASKYRA
Application Number
BLA125846
Sponsor
Fondazione Telethon ETS
NDC Codes
2
Dosage Forms
INJECTION
Routes
INTRAVENOUS
Active Ingredients
ETUVETIDIGENE AUTOTEMCEL

Indications and Usage

1 INDICATIONS AND USAGE WASKYRA ® is indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available. WASKYRA ® is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related hematopoietic stem cell donor is available. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.